Phase I Trial of Intraperitoneal (IP) Administration of a Measles Virus (MV) Strain Expressing the Human Carcinoembryonic Antigen (CEA) in Ovarian Cancer Patients

被引：0
|
作者：
Galanis, Evanthia [1 ]
Hartmann, Lynn C. [1 ]
Cliby, William A. [1 ]
Zollman, Paula [1 ]
Peethambaram, Prema P. [1 ]
Long, Harry J. [1 ]
Kaur, Judith S. [1 ]
Sloan, Jeff A. [1 ]
Poland, Gregory A. [1 ]
Peng, Kah-Whye [1 ]
Russell, Stephen J. [1 ]
机构：
[1] Mayo Clin, Coll Med, Rochester, MN USA
来源：
MOLECULAR THERAPY | 2006年 / 13卷
关键词：
D O I：
10.1016/j.ymthe.2006.08.809
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
729
引用
收藏
页码：S281 / S281
页数：1
相关论文
共 50 条
  • [1] Phase I trial of intraperitoneal (IP) administration of a measles virus (MV) derivative expressing the human carcinoembryonic antigen (CEA) in ovarian cancer patients.
    Galanis, E.
    Hartmann, L. C.
    Cliby, W.
    Zollman, P. J.
    Peethambaram, P. P.
    Long, H. J.
    Kaur, J. S.
    Sloan, J. A.
    Peng, K. W.
    Russell, S. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 262S - 262S
  • [2] Phase I trial of Intraperitoneal (IP) administration of a measles virus (MV) derivative expressing the human carcinoembryonic antigen (CEA) in recurrent ovarian cancer (OvCa)
    Galanis, E.
    Hartmann, L. C.
    Cliby, W.
    Peethambaram, P. P.
    Long, H. J.
    Kaur, J. S.
    Haluska, P., Jr.
    Sloan, J. A.
    Peng, K.
    Russell, S. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [3] Phase I Trial of Intraperitoneal Administration of an Oncolytic Measles Virus Strain Engineered to Express Carcinoembryonic Antigen for Recurrent Ovarian Cancer
    Galanis, Evanthia
    Hartmann, Lynn C.
    Cliby, William A.
    Long, Harry J.
    Peethambaram, Prema P.
    Barrette, Brigitte A.
    Kaur, Judith S.
    Haluska, Paul J., Jr.
    Aderca, Ileana
    Zman, Paula J.
    Sloan, Jeff A.
    Keeney, Gary
    Atherton, Pamela J.
    Podratz, Karl C.
    Dowdy, Sean C.
    Stanhope, C. Robert
    Wilson, Timothy O.
    Federspiel, Mark J.
    Peng, Kah-Whye
    Russell, Stephen J.
    CANCER RESEARCH, 2010, 70 (03) : 875 - 882
  • [4] Phase I/II Trial Oof Intratumoral and Resection Cavity Administration of an Edmonston Oncolytic Measles Virus (MV) Derivative Expressing the Human Carcinoembryonic Antigen (CEA) in Patients with Recurrent Glioblastoma
    Galanis, Evanthia
    Anderson, Keith
    Kurokawa, Cheyne B.
    Carrero, Xiomara W.
    Uhm, Joon H.
    Federspiel, Mark J.
    Buckner, Jan C.
    Lachance, Daniel H.
    Burns, Terence C.
    Giannini, Caterina
    Iankov, Ianko D.
    Parney, Ian F.
    MOLECULAR THERAPY, 2018, 26 (05) : 160 - 161
  • [5] Intraperitoneal (IP) Administration of an Oncolytic Measles Virus (MV) Strain Expressing the Sodium Iodine Symporter Gene in Patients (pts) with Advanced Ovarian Cancer (OvCa)
    Galanis, Evanthia
    Atherton, Pamela
    Dowdy, Sean
    Cliby, William
    Haluska, Paul, Jr.
    Long, Harry
    Aderca, Ileana
    Knutson, Keith
    Block, Matthew
    Federspiel, Mark
    Russell, Stephen
    Peng, Kah Whye
    Hartmann, Lynn
    MOLECULAR THERAPY, 2013, 21 : S6 - S7
  • [6] PHASE I TRIAL OF INTRATUMORAL AND RESECTION CAVITY ADMINISTRATION OF A MEASLES VIRUS DERIVATIVE EXPRESSING THE HUMAN CARCINOEMBRYONIC ANTIGEN IN PATIENTS WITH RECURRENT GLIOBLASTOMA MULTIFORME
    Galanis, Evanthia
    O'Neill, Brian
    Piepgras, David
    Meyer, Fredric
    Uhm, Joon
    Marks, Randolph
    Hammack, Julie
    Lachance, Daniel
    Anderson, S. Keith
    Wu, Wenting
    Russell, Stephen
    Buckner, Jan
    NEURO-ONCOLOGY, 2008, 10 (05) : 819 - 819
  • [7] Phase I trial of intratumoral (IT) administration of a NIS-expressing derivative manufactured from a genetically engineered strain of measles virus (MV)
    Liu, M. C.
    Peng, K-W
    Federspiel, M. J.
    Russell, S. J.
    Brunton, B. A.
    Zhou, Y.
    Packiriswamy, N.
    Hubbard, J. M.
    Loprinzi, C. L.
    Peethambaram, P. P.
    Ruddy, K. J.
    Allred, J. B.
    Galanis, E.
    Okuno, S. H.
    CANCER RESEARCH, 2019, 79 (04)
  • [8] Carcinoembryonic antigen-expressing oncolytic measles virus derivative in recurrent glioblastoma: a phase 1 trial
    Evanthia Galanis
    Katharine E. Dooley
    S. Keith Anderson
    Cheyne B. Kurokawa
    Xiomara W. Carrero
    Joon H. Uhm
    Mark J. Federspiel
    Alexey A. Leontovich
    Ileana Aderca
    Kimberly B. Viker
    Julie E. Hammack
    Randolph S. Marks
    Steven I. Robinson
    Derek R. Johnson
    Timothy J. Kaufmann
    Jan C. Buckner
    Daniel H. Lachance
    Terry C. Burns
    Caterina Giannini
    Aditya Raghunathan
    Ianko D. Iankov
    Ian F. Parney
    Nature Communications, 15
  • [9] Carcinoembryonic antigen-expressing oncolytic measles virus derivative in recurrent glioblastoma: a phase 1 trial
    Galanis, Evanthia
    Dooley, Katharine E.
    Anderson, S. Keith
    Kurokawa, Cheyne B.
    Carrero, Xiomara W.
    Uhm, Joon H.
    Federspiel, Mark J.
    Leontovich, Alexey A.
    Aderca, Ileana
    Viker, Kimberly B.
    Hammack, Julie E.
    Marks, Randolph S.
    Robinson, Steven I.
    Johnson, Derek R.
    Kaufmann, Timothy J.
    Buckner, Jan C.
    Lachance, Daniel H.
    Burns, Terry C.
    Giannini, Caterina
    Raghunathan, Aditya
    Iankov, Ianko D.
    Parney, Ian F.
    NATURE COMMUNICATIONS, 2024, 15 (01)
  • [10] A phase I/II trial of intraperitoneal (IP) cisplatin (CDDP) with IP gemcitabine (GEM) in patients (pts) with epithelial ovarian cancer.
    Sabbatini, P
    Aghajanian, C
    Hensley, M
    Tong, W
    Soignet, S
    Hoskins, W
    Flaherty, CO
    Pezzulli, S
    Barakat, R
    Spriggs, D
    CLINICAL CANCER RESEARCH, 2000, 6 : 4576S - 4576S
12345